Clinical implications of cyclooxygenase inhibition for gastrointestinal disease
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Philadelphia [u.a.]
Saunders
2001
|
| Schriftenreihe: | Gastroenterology clinics of North America
30,4 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV014062134 | ||
| 003 | DE-604 | ||
| 005 | 20150112 | ||
| 007 | t | ||
| 008 | 011218s2001 ad|| |||| 00||| eng d | ||
| 035 | |a (OCoLC)48549507 | ||
| 035 | |a (DE-599)BVBBV014062134 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 |a DE-19 |a DE-29 |a DE-578 |a DE-91 | ||
| 084 | |a YC 4700 |0 (DE-625)153226: |2 rvk | ||
| 245 | 1 | 0 | |a Clinical implications of cyclooxygenase inhibition for gastrointestinal disease |c James M. Scheiman guest ed. |
| 264 | 1 | |a Philadelphia [u.a.] |b Saunders |c 2001 | |
| 300 | |a XII S., S. 863 - 1066 |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Gastroenterology clinics of North America |v 30,4 | |
| 650 | 7 | |a Gastro-enterologie |2 gtt | |
| 650 | 7 | |a Oxygenases |2 gtt | |
| 650 | 4 | |a Cyclooxygenase Inhibitors | |
| 650 | 4 | |a Cyclooxygenases |x Inhibitors |x Therapeutic use | |
| 650 | 4 | |a Gastrointestinal Diseases |x drug therapy | |
| 650 | 4 | |a Gastrointestinal Diseases |x physiopathology | |
| 650 | 4 | |a Gastrointestinal system |x Diseases | |
| 650 | 0 | 7 | |a Prostaglandinsynthase |0 (DE-588)4175972-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Gastrointestinale Krankheit |0 (DE-588)4114483-1 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Gastrointestinale Krankheit |0 (DE-588)4114483-1 |D s |
| 689 | 0 | 1 | |a Prostaglandinsynthase |0 (DE-588)4175972-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Scheiman, James M. |e Sonstige |4 oth | |
| 830 | 0 | |a Gastroenterology clinics of North America |v 30,4 |w (DE-604)BV000613725 |9 30,4 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=009631215&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-009631215 | ||
Datensatz im Suchindex
| DE-BY-TUM_call_number | 1102/MED 430f 0018 A 154-30,4 |
|---|---|
| DE-BY-TUM_katkey | 2305346 |
| DE-BY-TUM_media_number | TEMP3287034 |
| _version_ | 1816714401635368960 |
| adam_text | CLINICAL IMPLICATIONS OF CYCLOOXYGENASE INHIBITION
FOR GASTROINTESTINAL DISEASE
CONTENTS
Preface xi
James M. Scheiman, MD
Prostaglandin Biology 863
Leslie J. Crofford
Prostaglandins (PGs) are mediators of physiologic functions and
pathologic responses. The diversity of PG activities is achieved
by cell and tissue specific generation of different stable PGs, mul¬
tiple PG receptors linked to different inrracellular signaling path¬
ways, and PG production pathways involving enzymes that are
induced to dramatically increase local PG production. This article
will review mechanisms of PG production and action. Dissecting
these biochemical and molecular pathways provides greater un¬
derstanding of the clinical pharmacology of available inhibitors
of PG production and may allow development of therapeutic
agents that can be applied to specific clinical situations, while
preserving PGs that play a role in normal physiology.
Mucosal Defense and Repair: Role of Prostaglandins in
the Stomach and Duodenum 877
Byron Cryer
When considering the diseases of the stomach and duodenum,
peptic ulcer disease has been the one of greatest clinical impact.
Although there are several components that contribute mechanis¬
tically to ulcer disease, it is recognized that gastroduodenal muco¬
sal prostaglandins play a central pathogenic role, especially in
ulcers related to the use of NSAIDs. As a result of understanding
the mechanisms of NSAID induced ulceration, the crucial func¬
tion that gastroduodenal mucosal prostaglandins have in mucosal
GASTROENTEROLOGY CLINICS OF NORTH AMERICA
VOLUME 30 • NUMBER 4 • DECEMBER 2001 V
defense and repair is appreciated. It now is held widely that
mucosal prostaglandin deficiency increases susceptibility to ulcer
formation and that exogenous administration of supplemental
prostaglandins reduces ulcer risk. This article reviews the role
that mucosal prostaglandins play in defense of the gastric and
duodenal mucosa against injury and ulceration.
Gastrointestinal Toxicity Associated with Nonsteroidal
Anti Inflammatory Drugs: Epidemiologic and
Economic Issues 895
Walter L. Straus and Joshua J. Ofman
The large body of literature on the gastrointestinal side effects of
NSAIDs has shown consistently that populations can be identified
that have a markedly elevated risk for these iatrogenic conditions.
These groups include the elderly, persons with prior history of
peptic ulcer disease, persons receiving anticoagulant and cortico
steroid therapy, and persons who require long term NSAID ther¬
apy. It is possible that several comorbites predispose patients to
gastrointestinal complications caused by NSAIDs, but few studies
have adjusted carefully for the possibility that concomitant use
or increased NSAID dose may account best for apparent associa¬
tion of comorbites as a risk factor for serious gastointestinal
events.
Gastointestinal Safety of COX 2 Specific Inhibitors 921
Christopher J. Hawkey
With the prolonged ingestion of aspirin or nonaspirin NSAIDs,
excavated ulcers develop in the stomach and duodenum, often
causing very few noticible symptoms, possibly because the anal¬
gesic effects of NSAIDs tend to mask the pain. Many long term
users of NSAIDs develop clinically significant ulcers or poten¬
tially life threatening ulcer complications that often result in seri¬
ous illness or death. Due to their markedly reduced propensity
to cause symptomatic ulcers, COX 2 inhibitors represent a major
advance in the therapy of patients with painful and inflammatory
conditions.
Helicobacter pylori and Non Steroidal
Anti Inflammatory Drugs 937
Francis K.L. Chan
The interaction between Helicobacter pylori and NSAIDs is not a
simple all or none relationship. Current evidence suggests that H.
pylori increases the risk of ulcer in patients who are about to start
NSAIDs, whereas NSAIDs cause the majority of ulcer complica¬
tion in chronic NSAID users irrespective of the H. pylori status. In
addition, H. pylori plays a more important role in ulcer bleeding
Vi CONTENTS
associated with low dose aspirin than in bleeding associated with
non aspirin NSAIDs. Eradication of H. pylori has been shown to
prevent recurrent ulcer bleeding associated with low dose aspirin
but not with non aspirin NSAIDs. With an increasing use of COX
2 selective NSAIDs and prophylactic low dose aspirin, the relative
importance of H. pylori in peptic ulcer disease is expected to in¬
crease.
Clinical Implications of Prostaglandin Inhibition in the
Small Bowel 953
Courtney W. Houchen
NSAIDs are among the most widely used class of drugs for the
treatment of arthritides and other painful conditions. The newer
selective cyclooxygenase 2 inhibitors have emerged as an im¬
portant option in the treatment of these conditions. The wide¬
spread acceptance of these agents has brought renewed attention
to the role of prostaglandin inhibition in gastroduodenal injury.
These newer agents appear to cause less gastroduodenal ulcer
ation and result in fewer significant gastrointestinal complications
than traditional NSAIDs. In this article, the author reviews the
less recognized complications of prostaglandin inhibition in the
small intestine.
Prostaglandin Biology in Inflammatory Bowel Disease 971
John L. Wallace
Prostaglandins are critical mediators of virtually every aspect
of mucosal defense, explaining in part why nonsteroidal anti
inflammatory drugs are able to cause injury throughout the gas¬
trointestinal tract. When inflamed, gastrointestinal prostaglandin
synthesis is derived largely from cyclooxygenase 2, in contrast to
the normal situation. These prostaglandins play an important
role in down regulating inflammation and in promoting repair.
Selective suppression of COX 2 has been shown, in experimental
models, to cause an exacerbation of colitis and to increase the
propensity for bacterial invasion of the intestinal mucosa.
Prostaglandin Inhibitors and the Chemoprevention of
Noncolonic Malignancy 981
Koyamangalath Krishnan and Dean E. Brenner
Gastrointestinal malignancies pose a significant world wide bur¬
den on health care. Advanced gastrointestinal malignancy is in¬
curable, and treatment is essentially palliative. Identification and
screening for early premalignant lesions and investigation into
newer methods to treat premalignant gastrointestinal conditions
is an area of active research. Gastrointestinal malignancies are
important and feasible targets for chemopreventive strategies.
This article focuses on the role of prostaglandins and cyclooxygen
CONTENTS vii
ases in non colonic gastrointestinal malignancies (esophagus and
stomach). The epidemiologic and experimental evidence to sup¬
port the rationale for the use of NSAID based chemoprevention
trials is also discussed.
Role of Cyclooxygenase Inhibitors for the Prevention of
Colorectal Cancer 1001
Elizabeth Stack and Raymond N. DuBois
Chronic use of NSAIDs has been shown to result in a 50%
reduction of risk and mortality from colorectal cancer. Well char¬
acterized targets of NSAIDs are the cyclooxygenase (COX) en¬
zymes for which two isoforms exist, COX 1 and COX 2. These
enzymes catalyze the key steps in the synthesis of prostaglandins
and thromboxane, which are bioactive lipid molecules derived
from arachidonic acid. These fatty acid metabolites sometimes are
referred to as eicosaniods and are involved in inflammation,
modulation of the immune response, apoptosis, and maintenance
of mucosal integrity. These molecules signal through G coupled
cell surface receptors or through peroxisome proliferator activi
ated (PPAR) nuclear receptors. There is a significant amount of
data supporting the role of cycloxygenase in the development of
colorectal neoplasia. The goal of this article is to provide a concise
review of the role of cyclooxygenase and NSAIDs in the preven¬
tion of colorectal cancer.
COX 2 Inhibitors: Are They Nonsteroidal
Anti Inflammatories with a Better Safety Profile? 1011
Lee S. Simon
In the treatment of arthritis, NSAIDs are some of the most com¬
monly used drugs, although the prescription of such drugs has
been questioned due to their inherent risks for gastrointestinal
compromise, platelet effects, and the potential for renal toxicity
with long term use. With the availability of celecoxib and rofec
oxib, 2 cyclooxygenase (COX 2) inhibitors (or COX 1 sparing
agents) as new forms of NSAIDs, these issues have become mag¬
nified not only in the context of risk to benefit ratios but also in
terms of pharmacoeconomics because they have been proven to
be equally efficacious as the nonselective NSAIDs, with an im¬
proved safety profile particularly within the gastrointestinal tract,
but at a significantly increased cost.
An Evidence Based Approach to the Gastrointestinal
Safety Profile of COX 2 Selective Anti Inflammatories 1027
Philip Schoenfeld
Evidence based medicine (EBM) provides frameworks for the
systematic review of study methodolgy and results. Thus, EBM
viii CONTENTS
frameworks facilitate assessing a study s ability to produce unbi¬
ased and accurate results and applying the results to the manage¬
ment of individual patients. Using EBM frameworks, published
literature about risk factors for serious NSAID associated gastro¬
intestinal (GI) disorders, GI safety of COX 2 selective NSAIDs,
and GI safety of co therapy of proton pump inhibitors and
NSAIDs are reviewed. This article concludes with evidence based
recommendations concerning which patients are at high risk for
serious NSAID associated GI disorders and which therapies are
most effective in reducing serious NSAID associated GI disorders.
Cumulative Index 1045
Subscription Information Inside back cover
CONTENTS ix
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV014062134 |
| classification_rvk | YC 4700 |
| ctrlnum | (OCoLC)48549507 (DE-599)BVBBV014062134 |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01922nam a2200445 cb4500</leader><controlfield tag="001">BV014062134</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20150112 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">011218s2001 ad|| |||| 00||| eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)48549507</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV014062134</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield><subfield code="a">DE-19</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-578</subfield><subfield code="a">DE-91</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YC 4700</subfield><subfield code="0">(DE-625)153226:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Clinical implications of cyclooxygenase inhibition for gastrointestinal disease</subfield><subfield code="c">James M. Scheiman guest ed.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Philadelphia [u.a.]</subfield><subfield code="b">Saunders</subfield><subfield code="c">2001</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XII S., S. 863 - 1066</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Gastroenterology clinics of North America</subfield><subfield code="v">30,4</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Gastro-enterologie</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Oxygenases</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cyclooxygenase Inhibitors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cyclooxygenases</subfield><subfield code="x">Inhibitors</subfield><subfield code="x">Therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gastrointestinal Diseases</subfield><subfield code="x">drug therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gastrointestinal Diseases</subfield><subfield code="x">physiopathology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gastrointestinal system</subfield><subfield code="x">Diseases</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Prostaglandinsynthase</subfield><subfield code="0">(DE-588)4175972-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Gastrointestinale Krankheit</subfield><subfield code="0">(DE-588)4114483-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Gastrointestinale Krankheit</subfield><subfield code="0">(DE-588)4114483-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Prostaglandinsynthase</subfield><subfield code="0">(DE-588)4175972-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Scheiman, James M.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Gastroenterology clinics of North America</subfield><subfield code="v">30,4</subfield><subfield code="w">(DE-604)BV000613725</subfield><subfield code="9">30,4</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=009631215&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-009631215</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV014062134 |
| illustrated | Illustrated |
| indexdate | 2024-11-25T17:57:35Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-009631215 |
| oclc_num | 48549507 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR DE-19 DE-BY-UBM DE-29 DE-578 DE-91 DE-BY-TUM |
| owner_facet | DE-355 DE-BY-UBR DE-19 DE-BY-UBM DE-29 DE-578 DE-91 DE-BY-TUM |
| physical | XII S., S. 863 - 1066 Ill., graph. Darst. |
| publishDate | 2001 |
| publishDateSearch | 2001 |
| publishDateSort | 2001 |
| publisher | Saunders |
| record_format | marc |
| series | Gastroenterology clinics of North America |
| series2 | Gastroenterology clinics of North America |
| spellingShingle | Clinical implications of cyclooxygenase inhibition for gastrointestinal disease Gastroenterology clinics of North America Gastro-enterologie gtt Oxygenases gtt Cyclooxygenase Inhibitors Cyclooxygenases Inhibitors Therapeutic use Gastrointestinal Diseases drug therapy Gastrointestinal Diseases physiopathology Gastrointestinal system Diseases Prostaglandinsynthase (DE-588)4175972-2 gnd Gastrointestinale Krankheit (DE-588)4114483-1 gnd |
| subject_GND | (DE-588)4175972-2 (DE-588)4114483-1 (DE-588)4143413-4 |
| title | Clinical implications of cyclooxygenase inhibition for gastrointestinal disease |
| title_auth | Clinical implications of cyclooxygenase inhibition for gastrointestinal disease |
| title_exact_search | Clinical implications of cyclooxygenase inhibition for gastrointestinal disease |
| title_full | Clinical implications of cyclooxygenase inhibition for gastrointestinal disease James M. Scheiman guest ed. |
| title_fullStr | Clinical implications of cyclooxygenase inhibition for gastrointestinal disease James M. Scheiman guest ed. |
| title_full_unstemmed | Clinical implications of cyclooxygenase inhibition for gastrointestinal disease James M. Scheiman guest ed. |
| title_short | Clinical implications of cyclooxygenase inhibition for gastrointestinal disease |
| title_sort | clinical implications of cyclooxygenase inhibition for gastrointestinal disease |
| topic | Gastro-enterologie gtt Oxygenases gtt Cyclooxygenase Inhibitors Cyclooxygenases Inhibitors Therapeutic use Gastrointestinal Diseases drug therapy Gastrointestinal Diseases physiopathology Gastrointestinal system Diseases Prostaglandinsynthase (DE-588)4175972-2 gnd Gastrointestinale Krankheit (DE-588)4114483-1 gnd |
| topic_facet | Gastro-enterologie Oxygenases Cyclooxygenase Inhibitors Cyclooxygenases Inhibitors Therapeutic use Gastrointestinal Diseases drug therapy Gastrointestinal Diseases physiopathology Gastrointestinal system Diseases Prostaglandinsynthase Gastrointestinale Krankheit Aufsatzsammlung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=009631215&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000613725 |
| work_keys_str_mv | AT scheimanjamesm clinicalimplicationsofcyclooxygenaseinhibitionforgastrointestinaldisease |